{
    "nct_id": "NCT06106308",
    "official_title": "A Phase 2, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-line Treatment of Metastatic Colorectal Cancer in Patients with a KRAS or NRAS Mutation",
    "inclusion_criteria": "* Histologically confirmed metastatic colorectal cancer.\n* Documented KRAS or NRAS mutation.\n* No previous systemic therapy in the metastatic setting.\n* Participants must be willing to submit archival tissue or undergo fresh biopsy.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Women of childbearing potential must use contraception or take measures to avoid pregnancy.\n* Imaging computed tomography (CT) or magnetic resonance imaging (MRI) of chest/abdomen/pelvis and other scans as necessary to document all sites of disease performed within 28 days prior to the first dose of onvansertib.\n* Must have acceptable organ function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Concomitant KRAS or NRAS and BRAF-V600 mutation or microsatellite instability high/deficient mismatch repair.\n* Prior treatment with a VEGF inhibitor, including bevacizumab or biosimilars.\n* Previous oxaliplatin treatment within 12 months prior to randomization, when arm open.\n* Known dihydropyrimidine dehydrogenase (DPD) deficiency.\n* Anticancer chemotherapy or biologic therapy administered within 28 days prior to the first dose of study drug.\n* Untreated or symptomatic brain metastasis.\n* Gastrointestinal (GI) disorder(s) that would significantly impede the absorption of an oral agent.\n* Unable or unwilling to swallow study drug.\n* Uncontrolled intercurrent illness.\n* Known hypersensitivity to fluoropyrimidine or leucovorin, irinotecan, or oxalipatin.\n* Abnormal glucuronidation of bilirubin; known Gilbert's syndrome.\n* Use of strong CYP3A4 or CYP2C19 inhibitors or strong CYP3A4 inducers.\n* QTc >470",
    "miscellaneous_criteria": ""
}